142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

307155
Effects of Medicare Part D and the Health Implications of Medication Therapy Management Eligibility Criteria

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Wednesday, November 19, 2014 : 8:45 AM - 9:00 AM

Junling Wang, PhD , Department of Clinical Pharmacy, University of Tennessee College of Pharmacy, Memphis, TN
Yanru Qiao , Department of Clinical Pharmacy, University of Tennessee College of Pharmacy
Ya-Chen Shih , University of Chicago Department of Medicine, Chicago, IL
Christina Spivey , Department of Clinical Pharmacy, University of Tennessee College of Pharmacy, Memphis, TN
Liyuan Li
Jim Wan, PhD , Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN
Shelley White-Means , University of Tennessee Department of Clinical Pharmacy, Memphis, TN
Samuel Dagogo-Jack , University of Tennessee Health Science Center, Memphis, TN
William Cushman , Memphis Veterans Affairs Medical Center, Memphis, TN
Marie Chisholm-Burns , University of Tennessee College of Pharmacy
Objectives: Determine whether the implementation of the Medicare Part D 2006 was associated with changes in differential racial and ethnic disparity patterns between the individuals ineligible for medication therapy management (MTM) services and MTM-eligible individuals. The urgency for modifying MTM eligibility criteria would be increased if the reduction of disparity not seen.

Methods: Data from the Medicare Current Beneficiary Survey were analyzed. A difference-in-differences analyses, difference-in-differences-in-differences-in-differences (DDDD) model, was used to examine changes in difference in disparities between the MTM-ineligible and MTM-eligible individuals from 2004-2005 to 2007-2008 in relation to the changes from 2001-2002 to 2004-2005. Disparities were examined in health outcomes, health services utilizations/costs, and medication utilization. Both main and sensitivity analyses were conducted by various regression models.

Findings: The main analysis found no significant DDDD values. For racial disparities, according to some sensitivity analyses, Part D implementation was associated with a reduction in greater racial disparities among the MTM-ineligible and MTM-eligible individuals in activities of daily living (DDDD=1.13; P=0.03 for one analysis) and instrumental activities of daily living (DDDD=0.95; P=0.03 for one analysis). For ethnic disparities, Part D implementation was associated with reduction in any greater disparities among the MTM-ineligible than MTM-eligible individuals in costs of physician visits (DDDD=-4613.71; P=0.04 for one analysis) and high risk medication utilization (DDDD=-0.10; P=0.03 for one analysis).

Conclusions: Part D implementation is not consistently associated with reductions in the disparity implications of the Medicare MTM eligibility criteria. The MTM eligibility criteria need to be modified in order to eliminate their disparity implications.

Learning Areas:

Public health or related education
Public health or related laws, regulations, standards, or guidelines
Public health or related organizational policy, standards, or other guidelines
Public health or related public policy
Public health or related research

Learning Objectives:
Demonstrate whether Part D implementation is consistently associated with reductions in the disparity implications of the Medicare MTM eligibility criteria.

Keyword(s): Health Care Access, Health Disparities/Inequities

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have spent over fifteen years in the fields of health outcomes research and health policy. My research has been funded by the National Institute on Aging/National Institutes of Health, American Association of Colleges of Pharmacy, Pharmaceutical Research and Manufactures of America Foundation, Eli Lilly, Pharmacy Quality Alliance and the Bureau of TennCare. I have published over 35 research articles in peer-reviewed journals, and have given almost 50 presentations in various professional meetings
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

Back to: 5025.0: Medicare and Medicaid Policy